Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 10/20 | 0.45 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.40 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.38 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168129 | 1.00 | TTK (0.45) | TTKPTK6FYNMAPKAPK5MC4R | |
| SCHEMBL24105199 | 0.94 | TTK (0.45) | TTKPTK6FYNMAPKAPK5MC4R | |
| SCHEMBL30168196 | 0.89 | TTK (0.44) | TTKPTK6FYNMAPKAPK5MC4R | |
| SCHEMBL30167789 | 0.89 | PTK6 (0.49) | TTKPTK6FYNMAPKAPK5MC4R | |
| SCHEMBL24105025 | 0.89 | PTK6 (0.49) | TTKPTK6FYNMAPKAPK5MC4R | |
| SCHEMBL24104678 | 0.89 | TTK (0.44) | TTKPTK6FYNMAPKAPK5MC4R | |
| SCHEMBL30168215 | 0.88 | PTK6 (0.45) | TTKPTK6FYNMC4R | |
| SCHEMBL24105033 | 0.88 | PTK6 (0.45) | TTKPTK6FYNMC4R | |
| SCHEMBL24105022 | 0.86 | TTK (0.52) | TTKMAPKAPK5AURKA | |
| SCHEMBL25174057 | 0.81 | TTK (0.52) | TTKMAPKAPK5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249893-A1 | NOVEL IMIDAZO-PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | TTK 4157/4885PTK6 2213/4885FYN 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.